Clinical trials: Dysmotility
Diabetes Mellitus, Diabetes Mellitus Complications
Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis
The purpose of this study is to evaluate the effects of multiple dose regimens of relamorelin on vomiting episodes, gastric emptying and gastroparesis symptoms in participants with Type 1 and Type 2 diabetes mellitus and…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
- Trial name
- NCT02357420
- Testing
- Relamorelin
- Where
- 98 sites in United States, Belgium and 5 more
- Volunteers
- 393 people
- Sponsor
- Allergan
Diabetes Mellitus, Diabetes Mellitus Complications
Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis
The purpose of this study is to evaluate the effects of RM-131 on gastric emptying, gastroparesis symptoms, and the safety and tolerability of RM-131 compared to placebo in patients with Type 1 and Type 2 diabetes mellitus and…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
- Trial name
- NCT01571297
- Testing
- RM-131
- Where
- 30 sites in United States
- Volunteers
- 204 people
- Sponsor
- Motus Therapeutics, Inc.
Diabetes Mellitus Type 1 and 2, Diabetes Mellitus Complications
Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis
The purpose of this study is to evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) profile and the safety and tolerability of RM-131 in patients with diabetes mellitus and delayed gastric emptying.
- Conditions
- Diabetes Mellitus Type 1 and 2, Diabetes Mellitus Complications, Gastroparesis, Gastrointestinal Motility Disorder
- Trial name
- NCT01394055
- Testing
- RM-131
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Motus Therapeutics, Inc.
Gastrointestinal Motility Disorder
A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects
This is a single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics (PK) of repeated IV doses of TD-8954 in healthy adults 18 to 45 years of age and healthy…
- Trial name
- NCT01644240
- Testing
- TD-8954
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Esophageal Motility Disorders
Esophageal Dysmotility and Dilatation After Laparoscopic Gastric Banding
The purpose of this study is to determine whether esophageal dysmotility and dilatation is an important complication in the long term follow-up following laparoscopic gastric banding for morbid obesity.
- Trial name
- NCT01234428
- Testing
- Laparoscopic surgery, gastric banding
- Where
- Switzerland
- Volunteers
- 167 people
- Sponsor
- Spital STS AG
Functional Dyspepsia
Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia
The study is conducted in patients with functional dyspepsia or chronic gastritis. The purpose of this study is to: assess whether the dose of Itopride Hydrochloride 150 mg extended release tablets, taken once daily has a similar…
- Trial name
- NCT06217393
- Testing
- Itopride Hydrochloride 150 mg extended release tablets, Itopride Hydrochloride 50 mg film coated tablets
- Where
- 19 sites in Armenia, Malaysia and 3 more
- Volunteers
- 564 people
- Sponsor
- Abbott
Gastrointestinal Dysmotility
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function
Post-operative administration of ipamorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial small and/or large bowel resection.
- Trial name
- NCT01280344
- Testing
- Saline Solution for Injection, Ipamorelin
- Where
- 45 sites in United States
- Volunteers
- 320 people
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
Gastrointestinal Dysmotility
Ulimorelin Study of Efficacy and Safety (ULISES 007)
Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection.
- Trial name
- ULISES (NCT01285570)
- Testing
- Ulimorelin Intravenously (IV), 5% dextrose in water
- Where
- 45 sites in United States, Hungary and 5 more
- Volunteers
- 332 people
- Sponsor
- Tranzyme, Inc.
Gastroparesis, Slow Transit Constipation
Comparison of the Atmo Motility Gas Capsule System to the Reference Standard
The study objective is to demonstrate the equivalence of the Atmo Motility Gas Capsule System with the predicate SmartPill in measuring gastric emptying time and colonic transit time through examination of device agreement.
- Conditions
- Gastroparesis, Slow Transit Constipation, IBS
- Trial name
- NCT05718505
- Testing
- Atmo Motility Gas Capsule System, SmartPill Monitoring System
- Where
- 2 sites in United States
- Volunteers
- 209 people
- Sponsor
- Atmo Biosciences Pty Ltd
Gastrointestinal Dysmotility
Ulimorelin Study of Efficacy and Safety (ULISES 008)
Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection
- Trial name
- NCT01296620
- Testing
- Ulimorelin Intravenously (IV), Ulimorelin Invtravenously (IV), 5% dextrose in water
- Where
- 50 sites in United States, Bulgaria and 4 more
- Volunteers
- 330 people
- Sponsor
- Tranzyme, Inc.
Idiopathic Gastroparesis
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects.
- Trial name
- NCT06899217
- Testing
- CIN-102 Dose 15mg, CIN-102 Dose 10mg
- Where
- 85 sites in United States
- Volunteers
- 416 people
- Sponsor
- CinDome Pharma, Inc.